All In Biotech

NDA 020216 · Wyeth Pharms

Premarin

Estrogens, Conjugated · Topical, Vaginal · Estrogen

Last checked: Nov 21, 2026Latest source record: Apr 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1978

Oct 16, 1978

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,166

241 Phase 3, 150 recruiting

FAERS reports

59,395

42,092 serious, 1,858 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.3) ] . Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.2 , 5.4) , and Clinical Studies (14.2 , 14.3) ] . The Women's...

What it is approved for

From the label in effect May 30, 2025.

PREMARIN (conjugated estrogens) vaginal cream is a mixture of estrogens indicated for: • Treatment of Atrophic Vaginitis and Kraurosis Vulvae ( 1.1 ) • Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause ( 1.2 ) 1.1 Treatment of Atrophic Vaginitis and Kraurosis Vulvae 1.2 Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause

Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PREMARIN · ESTROGENS, CONJUGATED 0.625MG/GM · CREAM, TOPICAL, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Estrogens" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • breast cancer9,645
  • breast cancer female8,869
  • drug ineffective3,460
  • nausea2,431
  • headache2,389
  • pain2,320
  • fatigue2,294
  • off label use2,238
  • dizziness1,698
  • breast cancer metastatic1,682
  • dyspnoea1,670
  • malaise1,620

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044,156
20053,642
20063,215
20071,690
20083,636
20095,174
20109,123
20112,686
20122,586
20132,158
20142,056
20152,473
20162,564
20171,999
20181,802
20192,168
20202,307
20211,531
20221,415
20231,088
2024857
2025644
2026420

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Premarin* (Estrogens, Conjugated)

2024 spending

$255M

Beneficiaries

231,894

610,592 claims

Per beneficiary

$1,100

$10.78 per unit

View as table
YearSpending
2020$298,132,949
2021$291,232,583
2022$281,548,605
2023$279,329,987
2024$254,990,018

Part B: Premarin (Estrogens, Conjugated) · HCPCS J1410

2024 spending

$28K

Beneficiaries

103

201 claims

Per beneficiary

$268

2024 ASP limit $377.83 per unit

View as table
YearSpending
2020$29,611
2021$30,866
2022$50,419
2023$27,894
2024$27,593

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,844 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.